Latest for Maple Syrup Urine Disease Type II
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Maple Syrup Urine Disease Type II
This page covers the intermediate and intermittent forms, which result from partial deficiency of the branched-chain alpha-ketoacid dehydrogenase (BCKDC) complex, a mitochondrial enzyme complex composed of four subunits required for degradation of leucine, isoleucine, and valine. Intermediate MSUD has residual enzyme activity of approximately 3-30% of normal, allowing some branched-chain amino acid (BCAA) metabolism but with progressive accumulation of toxic metabolites during catabolic stress (illness, infection, fasting).
Keep reading about Maple Syrup Urine Disease Type II
Unlike the neonatal presentation of classic MSUD, intermediate MSUD typically presents from months to years of age with progressive symptoms. Clinical features include developmental delay and progressive neurologic deterioration, muscle tone abnormalities (hypotonia alternating with hypertonia and spasticity), seizures, lethargy, behavioral changes, and metabolic acidosis during decompensation.
The characteristic maple-scented urine odor occurs during acute metabolic decompensation. Accumulation of branched-chain amino acids and their metabolites (particularly leucine metabolites) causes neurologic injury through multiple mechanisms including mitochondrial dysfunction and excitotoxicity. Without treatment, progressive neurodegeneration leads to severe disability.
What are the symptoms of Maple Syrup Urine Disease Type II?
These are common symptoms of Maple Syrup Urine Disease Type II, and how strong they are varies from person to person.
- Progressive developmental delay and neurologic deterioration
- Hypotonia and hypertonia
- Seizures and lethargy
- Metabolic acidosis during decompensation
- Elevated branched-chain amino acids in blood and urine
- Maple-scented urine
Who gets Maple Syrup Urine Disease Type II?
MSUD Type II shows autosomal recessive inheritance, affecting males and females equally across all ethnic groups. Presentation typically occurs from approximately 6 months to 3-4 years of age, though cases with delayed presentation into later childhood have been reported.
The age of presentation depends on the residual enzyme activity level and the specific genetic mutations; patients with slightly higher residual activity present later. Type II is rare, with significantly lower prevalence than classic (Type I) MSUD.
MSUD is far more common in some communities with founder variants, such as the Old Order Mennonite population, where it affects about 1 in 380 newborns, according to MedlinePlus. Prognosis with treatment is variable; early diagnosis and strict dietary management can slow progression and optimize developmental outcomes. Recurrence risk for siblings of affected individuals is 25% per pregnancy (assuming both parents are carriers). Prenatal diagnosis is possible through genetic testing or enzyme activity measurement in amniotic fluid.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Maple Syrup Urine Disease Type II
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Maple Syrup Urine Disease Type II resources
Reputable organizations and medical references for learning more about Maple Syrup Urine Disease Type II, including disease registries, foundation resources, and clinical guidelines.